What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Internal medicine, Immunology, Surgery, Myeloid leukemia and Leukemia are his primary areas of study.
Sergio Amadori has included themes like Gastroenterology and Oncology in his Internal medicine study.
Pharmacology and Clinical trial is closely connected to Cytarabine in his research, which is encompassed under the umbrella topic of Oncology.
His Surgery study which covers Acute leukemia that intersects with Leukopenia and Fever of unknown origin.
The various areas that Sergio Amadori examines in his Myeloid leukemia study include Adult Acute Myeloid Leukemia, Fms-Like Tyrosine Kinase 3 and Hazard ratio.
His studies deal with areas such as Myeloid, Cancer research, Tretinoin and Acute promyelocytic leukemia as well as Leukemia.
His most cited work include:
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. (2438 citations)
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel (2002 citations)
- Retinoic acid and arsenic trioxide for acute promyelocytic leukemia (834 citations)
What are the main themes of his work throughout his whole career to date?
Sergio Amadori mainly investigates Internal medicine, Myeloid leukemia, Immunology, Oncology and Surgery.
His studies link Gastroenterology with Internal medicine.
His work deals with themes such as Bone marrow, Transplantation and NPM1, which intersect with Myeloid leukemia.
His work carried out in the field of Transplantation brings together such families of science as Stem cell and Pediatrics.
His Oncology research incorporates themes from Clinical trial and Midostaurin.
His Leukemia study integrates concerns from other disciplines, such as Myeloid, Cancer, Tretinoin and Acute promyelocytic leukemia.
He most often published in these fields:
- Internal medicine (63.64%)
- Myeloid leukemia (33.52%)
- Immunology (30.68%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (63.64%)
- Oncology (28.13%)
- Myeloid leukemia (33.52%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Oncology, Myeloid leukemia, Transplantation and Midostaurin.
His study in Cytarabine, Maintenance therapy, Leukemia, Induction chemotherapy and Chemotherapy are all subfields of Internal medicine.
His Leukemia study combines topics from a wide range of disciplines, such as Randomized controlled trial and Retinoic acid.
His Myeloid leukemia study is related to the wider topic of Cancer research.
His Transplantation study integrates concerns from other disciplines, such as Minimal residual disease, Proportional hazards model, NPM1, Hazard ratio and European LeukemiaNet.
His research investigates the connection with Adult patients and areas like Progenitor cell which intersect with concerns in Immunology.
Between 2016 and 2021, his most popular works were:
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel (2002 citations)
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation (802 citations)
- Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial (174 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Sergio Amadori mostly deals with Internal medicine, Myeloid leukemia, Oncology, Midostaurin and Minimal residual disease.
His Internal medicine study frequently links to related topics such as Gastroenterology.
His research investigates the connection between Myeloid leukemia and topics such as Adult patients that intersect with issues in Progenitor cell, Immunology, Graft-versus-host disease and Central nervous system disease.
His work deals with themes such as Chemotherapy regimen and Flt3 mutation, which intersect with Midostaurin.
His studies deal with areas such as Disease, Stem cell and Transplantation as well as Minimal residual disease.
His Leukemia research integrates issues from Acute promyelocytic leukemia and Randomized controlled trial.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
